Cite
HARVARD Citation
Chen, W. et al. (n.d.). Improved outcome for patients with relapsed/refractory mantle cell lymphoma (MCL) who stop ibrutinib +/− rituximab for reasons other than progression of disease. Hematological oncology. p. 360. [Online].